Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Not Yet Opened 02-02 16:00:00 EST

7.37

-0.10

-1.34%

盘后7.35

-0.02-0.25%

19:28 EST

High7.60	Low7.27	Vol437.61K
Open7.44	D1 Closing7.47	Amplitude4.35%
Mkt Cap209.40M	Tradable Cap193.65M	Total Shares28.41M
T/O3.26M	T/O Rate1.67%	Tradable Shares26.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":7.37,"timestamp":1770066000000,"preClose":7.47,"halted":0,"volume":437612,"hourTrading":{"tag":"盘后","latestPrice":7.3518,"preClose":7.37,"latestTime":"19:28 EST","volume":6450,"amount":47526.9278,"timestamp":1770078493703,"change":-0.0182,"changeRate":-0.002469,"amplitude":0.003826},"delay":0,"changeRate":-0.013386880856760328,"floatShares":26275300,"shares":28412537,"eps":-2.46113,"marketStatus":"Not Yet Opened","change":-0.1,"latestTime":"02-02 16:00:00 EST","open":7.44,"high":7.595,"low":7.27,"amount":3263967.0429603998,"amplitude":0.043507,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.46113,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770109200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.47,"preHourTrading":{"tag":"盘前","latestPrice":7.4,"preClose":7.47,"latestTime":"09:29 EST","volume":2598,"amount":18912.0828048,"timestamp":1770042597009,"change":-0.07,"changeRate":-0.009371,"amplitude":0.025435},"postHourTrading":{"tag":"盘后","latestPrice":7.3518,"preClose":7.37,"latestTime":"19:28 EST","volume":6450,"amount":47526.9278,"timestamp":1770078493703,"change":-0.0182,"changeRate":-0.002469,"amplitude":0.003826},"volumeRatio":1.135874,"impliedVol":1.9093,"impliedVolPercentile":0.8884},"requestUrl":"/m/hq/s/ARCT","defaultTab":"news","newsList":[{"id":"2607040491","title":"Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040491","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040491?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:32","pubTimestamp":1769790721,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics ($ARCT) announced an update on their ongoing clinical study. Study Overview Arcturus Therapeutics is running a first-in-human...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arcturus-arct-2304-flu-vaccine-trial-reaches-phase-1-finish-line-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arcturus-arct-2304-flu-vaccine-trial-reaches-phase-1-finish-line-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT","BK4211","BK4139","ISBC"],"gpt_icon":0},{"id":"2605040504","title":"Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Cerus (CERS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605040504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605040504?lang=en_us&edition=fundamental","pubTime":"2026-01-24 00:51","pubTimestamp":1769187075,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) and C...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-arcturus-therapeutics-arct-cerus-cers-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-arcturus-therapeutics-arct-cerus-cers-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4112","BK4581","BK4137","XBI","BK4585","BK4198","LU0128526141.USD","LABU","LU0029874061.USD","ARCT","BK4588","CERS"],"gpt_icon":0},{"id":"2605479417","title":"Arcturus Therapeutics initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605479417","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605479417?lang=en_us&edition=fundamental","pubTime":"2026-01-23 05:10","pubTimestamp":1769116246,"startTime":"0","endTime":"0","summary":"Roth Capital initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $20 price target The company has two mid-stage programs with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","ARCT","BK4007"],"gpt_icon":0},{"id":"2605486415","title":"Analysts Conflicted on These Healthcare Names: Arcturus Therapeutics (ARCT), Newron Pharmaceuticals SpA (OtherNWPHF) and Aldeyra Therapeutics (ALDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605486415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605486415?lang=en_us&edition=fundamental","pubTime":"2026-01-21 23:20","pubTimestamp":1769008826,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcturus Therapeutics (ARCT – Research Report), Newron Pharmaceut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-arcturus-therapeutics-arct-newron-pharmaceuticals-spa-othernwphf-and-aldeyra-therapeutics-aldx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-arcturus-therapeutics-arct-newron-pharmaceuticals-spa-othernwphf-and-aldeyra-therapeutics-aldx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0029874061.USD","HCSG","BK4139","LU0128526141.USD","BK4588","BK4581","LABU","ARCT","BK4585","XLV","BK4137","ALDX"],"gpt_icon":0},{"id":"2603697714","title":"Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603697714","media":"Simply Wall St.","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603697714?lang=en_us&edition=fundamental","pubTime":"2026-01-14 15:20","pubTimestamp":1768375218,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at the Westin St. Francis Hotel in San Francisco, with Founder, President, CEO and Director Joseph E. Payne speaking.\nThis high-profile conference appearance offered Arcturus a platform to showcase its pipeline and corporate story to a concentrated audience of healthcare-focused investors and industry peers.\nWith this conference spotlight and recent share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings/news/does-arcturus-therapeutics-arct-jpm-conference-spotlight-cla","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings/news/does-arcturus-therapeutics-arct-jpm-conference-spotlight-cla","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1551013425.SGD","LU1084165304.USD","LU1244550577.SGD","LU1720051108.HKD","IE00BLSP4239.USD","LU0211327993.USD","LU0345770308.USD","IE00B775SV38.USD","LU0345769128.USD","LU1267930490.SGD","LU1363072403.SGD","IE000M9KFDE8.USD","LU0251132253.USD","IE00BKVL7J92.USD","LU1548497426.USD","LU1629891620.HKD","LU2430703095.HKD","LU2756315664.SGD","BK4581","LU2746668461.USD","LU0170899867.USD","BK4534","LU0006306889.USD","LU0345769631.USD","LU0211326839.USD","LU0820562030.AUD","BK4533","IE00BBT3K403.USD","IE00BFXG1179.USD","LU0683600562.USD","ARCT","LU0211326755.USD","IE00BZ1G4Q59.USD","IE00BHPRN162.USD","BK4516","IE00BWXC8680.SGD","LU2106854487.HKD","LU2264538146.SGD","LU2430703178.SGD","LU0234572021.USD","LU0106261372.USD","LU2430703251.USD","LU0320765489.SGD","LU0106831901.USD","LU0787776722.HKD","BK4139","LU0345770993.USD","LU1670627923.USD","LU0943347566.SGD","IE00BN8TJ469.HKD"],"gpt_icon":0},{"id":"2602031504","title":"Arcturus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602031504","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602031504?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:30","pubTimestamp":1767911415,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 5:15 p.m. Pacific Time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL9t9mTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2601892811","title":"Arcturus Therapeutics Holdings Inc : Citigroup Cuts Target Price to $7 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892811","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892811?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:26","pubTimestamp":1767702367,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2601086401","title":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2601086401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601086401?lang=en_us&edition=fundamental","pubTime":"2026-01-06 15:53","pubTimestamp":1767686032,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR InfrastructureJan 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL8N3Y7095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","LU2125154935.USD","BP","AGNC","AVY","ARVN","AGIO","SG9999014005.SGD","BA","ALNY","IE00B5TLWC47.USD","BK4532","BKNG","ADAM","ALHC","AIG","BMY","AAL","ARCT","BK4178","BOW","APGE","ALB","AXSM","BRLT","WMS","BIIB","BKD","LU0757428866.USD","SGXZ23171101.USD","LU0971096721.USD","BC","BLTE","EAT","ALL","BBWI","BBBY","ALGT","AMT","BALL","BBIO","BK4135","LU2249611893.SGD","AJG","NLY","AEO","DRUG","BAC","ALK","BK"],"gpt_icon":1},{"id":"2600439065","title":"UK's Mhra: Approved Zapomeran (Kostaive) Mrna Covid-19 Vaccine, for Immunisation of Individuals Aged 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2600439065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600439065?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:37","pubTimestamp":1767361079,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y3097:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2595748244","title":"BRIEF-Arcturus Therapeutics Holdings Files For Mixed Shelf Of Up To $500 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595748244","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595748244?lang=en_us&edition=fundamental","pubTime":"2025-12-31 06:40","pubTimestamp":1767134406,"startTime":"0","endTime":"0","summary":"BRIEF-Arcturus Therapeutics Holdings Files For Mixed Shelf Of Up To $500 Million - SEC FilingDec 30  - Arcturus Therapeutics Holdings Inc ARCT.O:ARCTURUS THERAPEUTICS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $500 MILLION - SEC FILINGSource text: [ID:n0001193805-25-001797]Further company coverage: ARCT.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y00JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2595748931","title":"Arcturus Therapeutics Files $500 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2595748931","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595748931?lang=en_us&edition=fundamental","pubTime":"2025-12-31 06:29","pubTimestamp":1767133755,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  late Tuesday filed a registration statement with the US Securities and Exchange Commission for the potential sale of up to $500 million of securities from time to time.The filing covers common and preferred shares, debt securities, warrants, rights, and units.Net proceeds are intended for working capital and general corporate purposes, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4539","ARCT","BK4007"],"gpt_icon":0},{"id":"2592118978","title":"Arcturus Therapeutics Files Initial Beneficial Ownership Statement for Controller Joseph Roberts","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118978","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592118978?lang=en_us&edition=fundamental","pubTime":"2025-12-20 06:20","pubTimestamp":1766182849,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. has filed an initial statement of beneficial ownership  with the SEC. The filing names Joseph Roberts as the beneficial owner, who serves as Controller at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL4dgGb7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Arcturus Therapeutics Files Initial Beneficial Ownership Statement for Controller Joseph Roberts","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2591707640","title":"BRIEF-Arcturus Therapeutics CFO Andy Sassine To Leave Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2591707640","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591707640?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:43","pubTimestamp":1765813431,"startTime":"0","endTime":"0","summary":"BRIEF-Arcturus Therapeutics CFO Andy Sassine To Leave Company Dec 15  - Arcturus Therapeutics Holdings Inc ARCT.O:ARCTURUS THERAPEUTICS HOLDINGS INC - CFO ANDY SASSINE TO LEAVE COMPANY - SEC FILINGARCTURUS THERAPEUTICS HOLDINGS INC - JOE ROBERTS APPOINTED INTERIM PRINCIPAL FINANCIAL OFFICER - SEC FILINGSource text: [ID:n0001193805-25-001734]Further company coverage: ARCT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XK05J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"gpt_icon":1},{"id":"2591964199","title":"Arcturus Therapeutics Holdings Inc - CFO Andy Sassine to Leave Company - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591964199","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591964199?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:32","pubTimestamp":1765805530,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XK05J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2591464195","title":"Arcturus Therapeutics Updates CFO Severance and Stock Option Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2591464195","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591464195?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:31","pubTimestamp":1765805485,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. has announced that there are no changes to the compensation terms for Daniel Roberts, who has been appointed as the company's principal financial officer and principal accounting officer. Mr. Roberts' employment agreement, as modified since 2018, includes a base salary of $219,580, bonus eligibility of up to 20% of base salary, and participation in the company's 401K, equity incentive, health care, and other benefit plans.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLb3T5mC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2582797320","title":"Arcturus Therapeutics Holdings Inc. reports 59% revenue decline for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797320","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797320?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:26","pubTimestamp":1762946784,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. reported total revenue of $17.2 million for the three months ended September 30, 2025, representing a decrease of $24.5 million or 59% compared to $41.7 million for the same period in 2024. The decline was primarily attributed to reduced revenue from arrangements with pharmaceutical and biotechnology partners and government agencies. During the period, the company continued to advance its ARCT-810 program for OTC deficiency, with no serious infusion-related reactions observed in ongoing Phase 2 protocols. Arcturus also progressed its LUNAR-CF clinical trials and maintained development activities for its platform, utilizing a portion of its cash balance to fund these initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL22lXlh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2582320805","title":"Arcturus Therapeutics Delays Financial Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2582320805","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582320805?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:05","pubTimestamp":1762945543,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. has announced a delay in filing its quarterly financial report on Form 10-Q for the period ended September 30, 2025. The company disclosed the delay in a Form 12b-25 notification to the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL1Q61by:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2582388951","title":"Arcturus Therapeutics Q3 Collaboration Revenue USD 14.153 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388951?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:22","pubTimestamp":1762809745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX864EC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2582680744","title":"Arcturus Therapeutics reports third quarter revenue of $17.2 million and net loss of $13.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582680744","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582680744?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:01","pubTimestamp":1762808515,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. reported a net loss of $13.5 million, or $0.49 per diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $6.9 million, or $0.26 per diluted share, for the same period in 2024. For the first nine months of 2025, the net loss was $36.7 million, or $1.35 per diluted share, down from $50.9 million, or $1.89 per diluted share, for the same period in 2024. Revenue for the third quarter was $17.2 million, a decrease of $24.5 million from the previous year, and revenue for the nine-month period was $74.8 million, a decline of $54.7 million compared to 2024. Cash, cash equivalents, and restricted cash totaled $237.3 million as of September 30, 2025. The company announced additional cost reductions planned for the fourth quarter to extend its cash runway into 2028. Arcturus also reported progress in its clinical pipeline, including interim Phase 2 data for its cystic fibrosis program and ongoing development of its OTC deficie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL96gMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2582880719","title":"Arcturus Therapeutics Holdings Inc -Additional Cost Reductions Planned in Q4 to Extend Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2582880719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582880719?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:01","pubTimestamp":1762808461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA1YRQ9T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":0.0014},{"period":"1month","weight":0.1792},{"period":"3month","weight":-0.1747},{"period":"6month","weight":-0.3964},{"period":"1year","weight":-0.5657},{"period":"ytd","weight":0.2023}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.084619},{"month":2,"riseRate":0.461538,"avgChangeRate":0.008047},{"month":3,"riseRate":0.25,"avgChangeRate":-0.05017},{"month":4,"riseRate":0.583333,"avgChangeRate":0.110815},{"month":5,"riseRate":0.583333,"avgChangeRate":0.094979},{"month":6,"riseRate":0.615385,"avgChangeRate":0.024246},{"month":7,"riseRate":0.538462,"avgChangeRate":0.096382},{"month":8,"riseRate":0.538462,"avgChangeRate":0.072518},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.052457},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.077832},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033635},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.064746}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}